 |
Catalyst Pharmaceutical Partners to Present CPP-115 Progress at the 2012 Epilepsy Pipeline Update Conference
01/31/12
|
14.2 KB |
|
| |
CORAL GABLES, Fla., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will present CPP-115 progress at the 2012 Epilepsy Pipeline Update Conference on Thursday, February 2nd at 11:20 a.m. PST. The confe...
Read more
|
|
Catalyst Pharmaceutical Partners, Inc. Announces FDA Designation of CPP-115 as a Fast Track Development Program
12/20/11
|
14.2 KB |
|
| |
CORAL GABLES, Fla., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been designated as a Fast Track development program by the FDA for the treatment of cocaine dependency.
"We are delighted that CPP-115...
Read more
|
|
Scientific Paper Regarding CPP-115 for the Treatment of Cocaine Addiction Accepted for Publication in the Journal of Medicinal Chemistry
12/15/11
|
16.6 KB |
|
| |
CORAL GABLES, Fla., Dec. 15, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Company) today announced that a scientific paper on CPP-115 describing preclinical data supporting its use as a treatment for cocaine addiction, its pharmacological target specificity, and its visual safety was accepted for publication in the...
Read more
|
|
Catalyst Pharmaceutical Partners, Inc. Announces Commencement of Phase I(a) Safety Study for CPP-115
12/13/11
|
14.2 KB |
|
| |
CORAL GABLES, Fla., Dec. 13, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it has commenced its first in man Phase I(a) safety study for its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor.
"We are extremely pleased to now have two drugs, CPP-115 and CPP-109, in the...
Read more
|
|
Catalyst Pharmaceutical Partners Announces Presentation to be Made at the American Epilepsy Society's 65th Annual Meeting
12/02/11
|
15.4 KB |
|
| |
CORAL GABLES, Fla., Dec. 2, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that a poster presentation demonstrating that CPP-115, Catalyst's next-generation GABA aminotransferase inhibitor, suppresses infantile spasms (IS) in the rat multiple-hit model will be made on December 3, 2011 at the American E...
Read more
|
|
Catalyst Pharmaceutical Partners Promotes Alicia Grande to Vice President and Chief Financial Officer
12/02/11
|
13.9 KB |
|
| |
CORAL GABLES, Fla., Dec. 2, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) ("Company") today announced that Alicia Grande, CPA, CMA, Catalyst's Corporate Controller and Chief Accounting Officer, has been promoted to Vice President, Chief Financial Officer and Treasurer, effective December 16, 2011. Catalyst also annou...
Read more
|
|
Catalyst Pharmaceutical Partners Announces Third Quarter 2011 Financial Results
11/15/11
|
22.3 KB |
|
| |
CORAL GABLES, Fla., Nov. 15, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the third quarter and nine months ended September 30, 2011. For the three months ended September 30, 2011, the Company reported a net loss of $1,127,841, or $0.05 per basic and diluted share, compared ...
Read more
|
|
Catalyst Pharmaceutical Partners Appoints Richard P. Rieger as Vice President, Commercial Operations
11/14/11
|
14.6 KB |
|
| |
CORAL GABLES, Fla., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) ("Company") today announced that Richard P. Rieger has been appointed as Vice President, Commercial Operations, effective immediately. Rieger brings extensive corporate development and management consulting experience to Catalyst from the phar...
Read more
|
|
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Public Offering of Common Shares and Warrants
11/02/11
|
15.2 KB |
|
| |
CORAL GABLES, Fla., Nov. 2, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has closed its previously announced offering of: (i) 3,046,740 shares of its common stock, and (ii) common stock purchase warrants to purchase an aggregate of 1,523,370 shares of the Company's common stock, to institutio...
Read more
|
|
UPDATE -- Catalyst Pharmaceutical Partners, Inc. Announces Public Offering of Common Shares and Warrants
10/28/11
|
14.9 KB |
|
| |
CORAL GABLES, Fla., Oct. 28, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has agreed to sell: (i) 3,046,740 shares of its common stock, and (ii) common stock purchase warrants to purchase an aggregate of 1,523,370 shares of the Company's common stock, in a firm commitment underwritten public ...
Read more
|
|
Catalyst Pharmaceutical Partners, Inc. Announces Public Offering of Common Shares and Warrants
10/28/11
|
14.7 KB |
|
| |
CORAL GABLES, Fla., Oct. 28, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has agreed to sell: (i) 3,046,740 shares of its common stock, and (ii) common stock purchase warrants to purchase an aggregate of 1,523,370 shares of the Company's common stock, in a firm commitment underwritten public ...
Read more
|
|
Catalyst Pharmaceutical Partners to Present at the 10th Annual BIO Investor Forum
10/21/11
|
12.4 KB |
|
| |
CORAL GABLES, Fla., Oct. 21, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will be making a presentation on Tuesday, October 25th at 11:00 a.m. PST at the 10th Annual BIO Investor Forum. The forum will be he...
Read more
|
|
Catalyst Pharmaceutical Partners Adopts Stockholder Rights Plan
09/21/11
|
14.0 KB |
|
| |
CORAL GABLES, Fla., Sept. 21, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) ("Company") today announced that its Board of Directors has adopted a Stockholder Rights Plan (the "Plan"). The Plan is designed to provide adequate time for the Board of Directors and the stockholders to assess an unsolicited takeover bid fo...
Read more
|
|
Catalyst Pharmaceutical Partners Announces Presentation of Data Regarding CPP-115 at the American Chemical Society Annual Fall Meeting
08/31/11
|
14.2 KB |
|
| |
CORAL GABLES, Fla., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that Dr. Richard B. Silverman, a renowned expert in the field of rational drug design, on the biochemistry of GABA aminotransferase (GABA-AT), and the lead inventor on the team that invented CPP-115, gave a presentation entitle...
Read more
|
|
Catalyst Pharmaceutical Partners Announces Second Quarter 2011 Financial Results
08/16/11
|
20.7 KB |
|
| |
CORAL GABLES, Fla., Aug. 16, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the second quarter and six months ended June 30, 2011. For the three months ended June 30, 2011, the Company reported a net loss of $1,394,151, or $0.06 per basic and diluted share, compared to a net l...
Read more
|
|
Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Efficacy Results Evaluating CPP-115 for the Treatment of Infantile Spasms
06/16/11
|
15.9 KB |
|
| |
CORAL GABLES, Fla., June 16, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced initial positive efficacy results from an investigator sponsored study of CPP-115 in an animal model of infantile spasms (IS). In this study, CPP-115 significantly reduced observed spasms for three times longer than vigabatrin ...
Read more
|
|
Catalyst Pharmaceutical Partners Announces First Quarter 2011 Financial Results
05/16/11
|
19.6 KB |
|
| |
CORAL GABLES, Fla., May 16, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the three month period ended March 31, 2011. The Company reported a net loss of $1,517,136, or $0.08 per basic and diluted share, compared to a net loss of $1,045,043, or $0.06 per basic and diluted sha...
Read more
|
|
Catalyst Pharmaceutical Partners Announces Presentation to be Made at ARVO 2011 Conference
04/28/11
|
12.8 KB |
|
| |
CORAL GABLES, Fla., April 28, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that a poster presentation of the visual field safety results obtained from its previously completed, double-blind, placebo-controlled trial in cocaine dependent subjects (CPP-01004) will be made on May 5, 2011 at the leading ...
Read more
|
|
Catalyst Pharmaceutical Partners to Present at the Antiepileptic Drug Trials XI Conference
04/21/11
|
12.5 KB |
|
| |
CORAL GABLES, Fla., April 21, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will be making a presentation on Friday, April 29, 2011 at 2:55pm ET at the Antiepileptic Drug Trials XI Conference, an in-depth, t...
Read more
|
|
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2010 Financial Results
04/01/11
|
23.1 KB |
|
| |
CORAL GABLES, Fla., April 1, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended Decembe...
Read more
|
|
|
